New immunotherapy cocktail aims to tackle lymphoma without chemo
NCT ID NCT05783596
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study tests whether combining two immunotherapy drugs, glofitamab and obinutuzumab, can safely and effectively treat people newly diagnosed with follicular lymphoma or marginal zone lymphoma. About 47 participants who have not had prior treatment will receive the drug combination. The goal is to see how many achieve a complete metabolic response (cancer disappearance on scans) by the end of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Mount Sinai Medical Center
New York, New York, 10128, United States
Conditions
Explore the condition pages connected to this study.